Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan

Rheumatoid Arthritis Clinical Trial

— PASSRRA  

Official title:

Post-Authorization Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03348046
• Other study ID #: RMS-JOR-2015-01
• Status: Completed
• Start date: March 23, 2017
• Est. completion date: April 14, 2019

Study information

• Verified date: March 2020
• Source: Hikma Pharmaceuticals LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this observational study is to assess the safety and effectiveness of biosimilar Infliximab in patients with rheumatoid arthritis(RA) in Jordan where no visits or intervention(s) additional to the daily practice will be performed

Description:

A multi-center, observational, prospective, cohort study to assess the safety and effectiveness of biosimilar Infliximab (Remsima®) in patients with rheumatoid arthritis in Jordan. Biologic naïve patients will receive Remsima® in accordance with standard medical care and the approved label and will be followed over a period of 34 weeks (8.5 months). Outcomes including occurrence of adverse events (AEs), mean changes in disease activity and health assessment in each cohort will be measured and compared

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: April 14, 2019
• Est. primary completion date: April 14, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients (age =18 years)

• Biologic naïve patients with active RA diagnosed according to the revised 1987 American College of Rheumatology (ACR) (Arnett et al. 1988) or 2010 ACR / European League Against Rheumatism (EULAR) Rheumatoid Arthritis classification criteria (Aletaha et al. 2010)

• Patients should be receiving a stable dose Methotrexate (MTX) for at least 3 months prior to enrolment, and still have active disease defined as erythrocyte sedimentation rate (ESR) =28 mm/h and swollen and tender joints = 6

• Absence of tuberculosis demonstrated by negative chest X-ray

Exclusion Criteria:

• Patient <18 years

• Previous treatment with biologics

• Patients who meet any of the contraindications to the administration of infliximab

• Previous or concurrent malignancies

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Drug:
• Biosimilar Infliximab
A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg

Locations

Country	Name	City	State
Jordan	Prince Hamza Hospital	Amman
Jordan	Jordan University of Science and Technology- King Abdallah University Hospital	Irbid

Sponsors (2)

Lead Sponsor	Collaborator
Hikma Pharmaceuticals LLC	Syneos Health

Country where clinical trial is conducted

Jordan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of adverse events (AEs) and serious adverse events (SAEs) to Remsima®	Rate of AEs leading to permanent treatment discontinuation and rate of clinically relevant changes in laboratory tests will be calculated	8.5 months
Secondary	Mean changes in disease activity scores (DAS28)- Number of swollen joints	The Disease Activity Score (DAS) measures the disease activity in patients with Rheumatoid Arthritis (RA). DAS28 is a validated simplified tool in which twenty-eight joints are measured. The number of swollen joints will be assessed.	8.5 months, changes between baseline and last visit will be compared between visits using repeated measure analyses
Secondary	Mean changes in disease activity scores (DAS28)-Number of tender joints	The Disease Activity Score (DAS) measures the disease activity in patients with Rheumatoid Arthritis (RA). DAS28 is a validated simplified tool in which twenty-eight joints are measured. The number of tender joints will be assessed.	8.5 months, changes between baseline and last visit will be compared between visits using repeated measure analyses
Secondary	Mean changes in disease activity scores (DAS28)-ESR (Erythrocyte Sedimentation Rate)	The Disease Activity Score (DAS) measures the disease activity in patients with Rheumatoid Arthritis (RA). DAS28 is a validated simplified tool in which twenty-eight joints are measured.; ESR (Erythrocyte Sedimentation Rate) will be measured in mm/hr.	8.5 months, changes between baseline and last visit will be compared between visits using repeated measure analyses
Secondary	Mean changes in disease activity scores (DAS28)- Global assessment of disease activity on a 100 mm Visual Analogue Scale (VAS)	The Disease Activity Score (DAS) measures the disease activity in patients with Rheumatoid Arthritis (RA). DAS28 is a validated simplified tool in which twenty-eight joints are measured.; Patients will be asked to make a global assessment of disease activity on a 100 mm Visual Analogue Scale (VAS) measured by units on scale.; Number of swollen and tender joints, Erythrocyte Sedimentation Rate and global assessment of disease activity on a 100 mm Visual Analogue Scale (VAS) are then fed into a complex mathematical formula to produce the overall disease activity score.; The DAS28 provides a number on a scale from 0 to 10 indicating the current activity of the RA of the patient. A DAS28 above 5.1 means high disease activity whereas a DAS28 below 3.2 indicates low disease activity. Remission is achieved by a DAS28 lower than 2.6.	8.5 months, changes between baseline and last visit will be compared between visits using repeated measure analyses
Secondary	Mean changes in Disability Index of the Health Assessment Questionnaire (HAQ-DI)	The Health assessment questionnaire disability index (HAQ-DI) is a questionnaire for the assessment of Rheumatoid Arthritis. The reported data from patients include the amount of difficulty they have in performing some of their activities. Each question asks on a scale ranging from 0 to 3 if the categories can be performed without any difficulty (scale 0) up to cannot be done at all (scale 3).	8.5 months, changes between baseline and last visit will be compared between visits using repeated measure analyses